We have highlighted, in a recent blog entry, industry efforts at harmonizing various standards established by leading industry bodies for the development of cell therapies. While these efforts are aimed at globally addressing issues of standardization, it is individual labs who are faced with day-to-day decisions as potential cell therapies are taken through the development stages.
in order to address such issues, the National Institute of Standards and Technology is organizing a two-day workshop, titled “Strategies to Achieve Measurement Assurance for Cell Therapy Products”, the aim of which is to provide scientists and researchers with concrete feedback on the best practices to achieve measurement consistency and reliability.
The workshop has been designed to address three focus areas: Cell counting, cell viability and potency assays.
Akron will participate in the session on Potency Assays, which will focus on best strategies and methods to achieve standardization of cellular assays such as the endothelial cell tube formation assay.
The session is built around the recent paper “Critical elements in the development of cell therapy potency assays for ischemic conditions” which Akron’s Dr. Claudia Zylberberg co-authored with Dr. Yael Porat (BioGenCell), Dr. Eytan Abraham (Lonza), Dr. Ohad Karnieli (Pluristem), Dr. Sagi Nahum (Pluristem) and Dr. Juliana Woda (Juventas) and which was published in Cytotherapy earlier this year.
Alongside Akron, all authors of the paper will participate in the session.
The workshop runs on May 11 and May 12 on NIST’s campus in Gaithersburg. For more information, click here.